Acted like it's already bigger: a recent, in-motion company decision that only makes sense if the step-up is real
The model's full reasoning — Q3 2016 call → NO我们根据提供的财报电话会议记录来判断。管理层是否描述了公司最近做出的、已经采取行动的具体决定,该决定扩大了公司的业务范围,并且管理层将这一决定归因于已经存在的实际需求或业务,而不是希望中的需求或市场预测。 在电话会议中,管理层提到了几个项目,但我们需要寻找一个具体的、最近的决定,该决定扩大了公司的能力或业务,并且是基于实际需求。 例如,关于margetuximab的SOPHIA试验,他们提到正在继续入组患者并激活试验点,但这是试验的常规进展,不是扩大业务的决定。关于enoblituzumab,他们提到组合研究已进入剂量扩展队列,但这也是试验进展。 关于MGD010,他们提到Takeda决定终止合作,MacroGenics重新获得全球权利,并计划继续推进。这可能是扩大业务的决定,但这是基于Takeda的决定,而不是基于实际需求。 关于MGA012,他们提到IND已获FDA批准,并正在启动1期临床试验。这是新药进入临床,但这是计划中的,不是基于实际需求。 关于MGD014和MGD013,他们提到计划在2017年提交IND,但这是未来计划。 管理层没有明确描述一个最近做出的、已经采取行动的具体决定,该决定扩大了公司的能力或业务,并且是基于实际需求。他们提到了一些进展,但都是常规的临床试验进展,没有提到因需求增加而扩大产能、招聘、增加设施等。 因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| HCKT | The Hackett Group, Inc. | Q1 2024 | 2024-05-08 | C |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| PDS | Precision Drilling Corporation | Q1 2024 | 2024-04-25 | B |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| CHT | Chunghwa Telecom Co., Ltd. | Q4 2023 | 2024-01-30 | C |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| GRBK | Green Brick Partners, Inc. | Q3 2023 | 2023-11-01 | B |
| OPAD | Offerpad Solutions Inc. | Q3 2023 | 2023-11-01 | C |
| FSBC | Five Star Bancorp | Q3 2023 | 2023-10-31 | B |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| TGLS | Tecnoglass Inc. | Q2 2023 | 2023-08-08 | A |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| ET | Energy Transfer LP | Q2 2023 | 2023-08-02 | C+ |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| TSN | Tyson Foods, Inc. | Q2 2023 | 2023-05-08 | D |
| THS | TreeHouse Foods, Inc. | Q1 2023 | 2023-05-08 | B+ |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| TGT | Target Corporation | Q4 2022 | 2023-02-28 | C |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| WGO | Winnebago Industries, Inc. | Q1 2023 | 2022-12-16 | D |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| CIG | Companhia Energética de Minas Gerais | Q3 2022 | 2022-11-16 | C+ |
| PKOH | Park-Ohio Holdings Corp. | Q3 2022 | 2022-11-13 | B |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| TWO | Two Harbors Investment Corp. | Q2 2022 | 2022-08-04 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| UPWK | Upwork Inc. | Q2 2022 | 2022-07-27 | C+ |
| JBHT | J.B. Hunt Transport Services, Inc. | Q2 2022 | 2022-07-19 | C+ |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| ADSE | ADS-TEC Energy PLC | Q4 2021 | 2022-04-28 | D |
| ZENV | Zenvia Inc. | Q4 2021 | 2022-03-17 | C+ |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| FORM | FormFactor, Inc. | Q4 2021 | 2022-02-02 | B |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| LMAT | LeMaitre Vascular, Inc. | Q3 2021 | 2021-10-29 | C+ |
| MD | Pediatrix Medical Group, Inc. | Q3 2021 | 2021-10-28 | B |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| LOPE | Grand Canyon Education, Inc. | Q2 2021 | 2021-08-08 | C |
| GNK | Genco Shipping & Trading Limited | Q2 2021 | 2021-08-07 | A |
| EMR | Emerson Electric Co. | Q3 2021 | 2021-08-04 | B+ |
| AX | Axos Financial, Inc. | Q4 2021 | 2021-07-29 | C+ |
| JPM | JPMorgan Chase & Co. | Q2 2021 | 2021-07-13 | A |
| PRPO | Precipio, Inc. | Q3 2018 | 2018-11-19 | D |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| ALKS | Alkermes plc | Q3 2018 | 2018-10-23 | C |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| NOVT | Novanta Inc. | Q4 2017 | 2018-05-12 | B+ |
| FSS | Federal Signal Corporation | Q1 2018 | 2018-05-12 | A |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| AVT | Avnet, Inc. | Q2 2018 | 2018-01-25 | B |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| MITK | Mitek Systems, Inc. | Q4 2017 | 2017-11-07 | C+ |
| IR | Ingersoll-Rand Plc | Q3 2017 | 2017-10-25 | B |
| SBFG | SB Financial Group, Inc. | Q3 2017 | 2017-10-20 | A |
| STKL | SunOpta Inc. | Q2 2017 | 2017-08-09 | C+ |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| PPG | PPG Industries, Inc. | Q1 2017 | 2017-04-20 | C |
| ATO | Atmos Energy Corporation | Q1 2017 | 2017-02-08 | A |
| THRM | Gentherm Incorporated | Q2 2016 | 2016-07-28 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
| ENLC | EnLink Midstream, LLC | Q4 2015 | 2016-02-17 | C+ |
| SON | Sonoco Products Company | Q4 2015 | 2016-02-11 | B |
JBHT · Q2 2022 → YESThe question is about whether management describes a specific recent decision the company made and is acting on that enlarges what they can do, justified by real existing demand, not hoped-for. YES In the transcript, management describes a concrete recent decision to expand capacity in multiple segments, already in motion and justified by real, current demand rather than forecasts. For Dedicated: "After selling 600 trucks in Q1, we sold slightly over 800 trucks in the second quarter... We've added nearly 2, 200 trucks to our business in the last 12 months... This unprecedented demand and growth for our highly engineered Fleet Service has put a strain on the organization, and the team has responded extremely well to the challenge." They are actively onboarding new business with strong backlog and pipeline, and will hold trades on roughly 4,000 tractors this year to support replacement and growth. For Intermodal: "Demand for our capacity continues to be greater than our ability to serve that demand... volumes by month for the quarter were up 4% in April, up 9% in May and up 10% in June on a year-over-year basis.
PRPO · Q3 2018 → YESThe question is: Does management describe at least one SPECIFIC DECISION THE COMPANY ITSELF RECENTLY MADE AND IS ALREADY ACTING ON — within roughly the last quarter or two — that visibly ENLARGES what...YES The transcript shows management describing a concrete, recent decision to expand the sales force by hiring top-notch individuals in Q3, resulting in a 10-member team that contributed to pathology services revenue growth of nearly 50% from the prior quarter. This is tied directly to real business activity: the sales team’s traction in securing new customers and converting pipeline, with management noting the growth is already occurring and expecting continued acceleration. Separately, they describe launching HemeScreen externally after internal validation, citing immediate real demand through numerous orders received from physicians just weeks after launch, which enlarges their offering and is presented as a meaningful step toward capturing 2019 revenue. Both examples meet the criteria as specific, already-in-motion enlargements justified by current, visible business rather than forecasts.
LOPE · Q2 2021 → YESThe question is about whether management describes a specific recent decision that enlarges the company's capabilities, based on real existing demand. YES Management describes GCE’s recent, concrete decision to expand its Orbis platform by signing contracts for new partners in Southern California and New York City markets and opening medical lab science programs with two additional partners. This enlarges the company’s off-campus classroom and laboratory capacity (currently 31 sites, targeting 40 by 2022). The decision is already in motion: one new site opened in spring 2021, two more in summer 2021, and further openings are scheduled for fall 2021 and 2022. Management ties this directly to real, already-arriving business—specifically, the 13.2% year 2021 enrollment growth at Orbis sites (up 19% in nursing) and the fact that partner institutions are actively seeking additional revenue streams because they derive 14% of revenues from GCE/Orbis programs and want to do more.